{"filings":[{"id":1204077,"accession_number":"0001534120-26-000044","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-06-23T11:01:57+00:00","items":["5.02"],"status":"ready","headline":"Avalo Therapeutics appoints Ron Philip to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ron Philip appointed to board effective June 23, 2026; will serve until 2027 annual meeting.","Appointed to Compensation Committee and Science, Development and Commercial Advisory Committee.","Received non-qualified stock option to purchase 40,200 shares, vesting over 3 years.","Mr. Philip most recently was CEO of Orbital Therapeutics until its acquisition by Bristol-Myers Squibb in Dec 2025.","Board determined Mr. Philip satisfies Nasdaq independence standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1065876,"accession_number":"0001534120-26-000042","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-06-16T11:18:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics expands pipeline with AVTX-010, a long-acting anti-IL-1β mAb; IND planned H1 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AVTX-010 is an engineered anti-IL-1β mAb for hidradenitis suppurativa and other inflammatory disorders.","IND submission for AVTX-010 expected in the first half of 2027.","Building on abdakibart Phase 2 LOTUS data and the IL-1β pathway conviction.","CEO cites less frequent dosing as key driver for physician and patient preference.","Follows transformational financing completed in May 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027358,"accession_number":"0001534120-26-000040","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-06-12T20:06:58+00:00","items":["3.02","3.03","5.02","5.03","9.01"],"status":"ready","headline":"Avalo exchanges Series C shares to lift beneficial ownership cap; revises exec severance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged 4,294.675 Series C shares for new Series C-1 shares, removing restriction that capped beneficial ownership at 4.99% (now 9.99%).","After exchange, 4,085.379 Series C shares remain outstanding.","Amended employment agreements for CEO Neil, CFO Sullivan, CMO Doyle, and CBO Boyd, changing severance and change-in-control terms.","CEO Neil gets 18-month base salary severance (others 12 months); on change-in-control termination, 1.5x base + 1x target bonus (others 1x/1x).","Pre-amendment options vest fully on qualifying termination; exercise period extended to 12 months for CEO/CFO, 6 months for CMO/CBO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918636,"accession_number":"0001534120-26-000036","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-06-08T20:19:40+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Avalo Therapeutics shareholders approve Second Amended ESPP at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["ESPP share reserve set at 961,608 shares; annual evergreen of lesser of 4M shares or 1% of outstanding common stock through 2036.","Purchase price at 85% of FMV on either offering date or purchase date, whichever is lower; payroll deductions up to 15% of earnings.","All seven director nominees elected with >99% of votes cast in favor (e.g., Michael Heffernan: 21,101,978 for, 624 withheld).","Ratification of Ernst & Young as independent auditor approved with 22,513,332 for vs 153,320 against and 5,632 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49926,"accession_number":"0001534120-26-000032","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-05-13T11:00:44+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo reports Q1 net loss $19.6M, Phase 2 HS trial meets endpoints, $431M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 LOTUS topline: HiSCR75 absolute improvement 42.2% (150mg) and 42.9% (300mg) vs placebo 25.6%; p=0.018 and 0.015.","Q1 2026 net loss $19.6M ($0.98 loss/share) vs $13.1M prior year, driven by higher R&D costs.","Cash $82.0M as of Mar 31, 2026; subsequent public offering raised gross $431.3M (net $405M), extending runway into 2029.","Milestone Buyout Option: paid $2.25M for option to replace $15M milestone with $5.125M payment upon Phase 3 start.","R&D expense $14.0M (+$4.9M YoY); G&A $6.9M (+$1.3M YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93491,"accession_number":"0001104659-26-056482","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 19.73M shares at $17.75/share plus 1.4M pre-funded warrants at $17.749/warrant.","Underwriters exercised overallotment option for 3.17M additional shares in full on May 6.","Net proceeds estimated at $405M; proceeds to fund clinical development of abdakibart through Phase 3 topline data.","Preliminary cash, cash equivalents and short-term investments as of March 31, 2026: $82.0M.","Expected closing May 7, 2026; cash runway expected to extend into 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93490,"accession_number":"0001534120-26-000028","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics Phase 2 LOTUS trial meets primary endpoint; HiSCR75 rates 42.2% and 42.9% for abdakibart in HS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Abdakibart 150 mg achieved 42.2% HiSCR75 (p=0.018), 300 mg achieved 42.9% (p=0.015); placebo 25.6%.","Statistically significant benefit on secondary endpoints HiSCR50, change in IHS4, and draining tunnel count.","Abdakibart well tolerated; most TEAEs mild to moderate, no neutropenia, serious infections, or opportunistic infections.","Response similar in patients with and without prior biologic exposure.","Avalo plans to advance abdakibart into a registrational Phase 3 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93489,"accession_number":"0001534120-26-000026","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Avalo Therapeutics buys option to reduce AlmataBio milestone from $15M to $7.375M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pays $2.25M upfront for 90-day option to pay $5.125M (cash/stock) in lieu of $15M Phase 3 dosing milestone.","If option not exercised, $12.75M milestone remains due upon first patient in Phase 3 trial.","Agreement amends March 2024 Merger Agreement for AlmataBio acquisition.","Effective April 26, 2026; option decision due within 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105160,"accession_number":"0001534120-26-000016","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Avalo Therapeutics directors to not stand for re-election at 2026 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jonathan Goldman and Mitchell Chan will not stand for re-election to the Board at the 2026 Annual Meeting.","They will continue to serve as board members until the 2026 Annual Meeting.","Decisions are not due to any disagreement with the Company regarding operations, policies, or practices.","The Board expressed gratitude for their service and contributions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105159,"accession_number":"0001534120-26-000010","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo Therapeutics reports 2025 net loss of $78.3M; Phase 2 HS topline data due Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $78.3M ($5.84 per share) vs $35.1M in 2024; operating expenses rose to $73M.","Cash, equivalents and short-term investments $98.3M as of Dec 31, 2025; expected runway into 2028.","R&D expenses $50.1M, up $25.6M YoY driven by Phase 2 LOTUS trial costs for abdakibart (AVTX-009).","Topline data from Phase 2 abdakibart trial for hidradenitis suppurativa expected in Q2 2026.","G&A expenses $22.9M, up $5.7M primarily from stock-based compensation and headcount additions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105158,"accession_number":"0001534120-26-000003","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics estimates $98M cash as of Dec 31, 2025 in preliminary update","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, cash equivalents and short-term investments of ~$98M as of December 31, 2025.","Estimate is unaudited and preliminary; actual year-end results may differ materially.","Company also posted an updated investor presentation highlighting its IL-1β pipeline.","Full financial results to be reported in the 2025 Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121418,"accession_number":"0001534120-25-000022","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo posts updated investor presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company filed 8-K announcing updated investor presentation posted on its website.","Presentation is a corporate overview focused on IL-1β therapies pipeline.","No financial results, trial data, or guidance changes included in the filing text.","Presentation will be used in meetings with investors going forward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121417,"accession_number":"0001534120-25-000017","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo Therapeutics Q3 net loss $30.6M; completes Phase 2 LOTUS enrollment for AVTX-009","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed enrollment in Phase 2 LOTUS trial (~250 adults) for AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.","Cash and short-term investments $111.6M as of Sept 30, 2025; expected to fund operations into 2028.","Net loss $30.6M in Q3 2025 vs net income $23.0M in Q3 2024; basic diluted EPS -$2.19.","R&D expenses $13.6M (up $4.1M YoY) driven by LOTUS trial; G&A $5.6M (up $1.3M).","Appointed Kevin Lind to Board; expanded leadership with new Chief Business Officer and SVP HR."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121416,"accession_number":"0001534120-25-000013","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo completes Phase 2 LOTUS enrollment for AVTX-009; topline data mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrolled ~250 patients, exceeding the 222-patient target.","Trial is randomized, double-blind, placebo-controlled with two AVTX-009 dose regimens.","Primary endpoint is HiSCR75 at Week 16; topline results expected mid-2026.","CEO Dr. Garry Neil cited strong investigator and patient engagement due to high unmet need.","Trial identifier NCT06603077; details at clinicaltrials.gov or lotustrial.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121415,"accession_number":"0001534120-25-000011","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics posts updated investor presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation dated October 2025 describes pipeline of novel IL-1β therapies.","No new clinical data, financial results, or guidance changes included in update.","Presentation used for routine investor meetings; no material events announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121414,"accession_number":"0001534120-25-000009","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics expands leadership with CBO and SVP HR appointments","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Taylor Boyd named Chief Business Officer; base salary $465k, target bonus 40%, 275k stock option inducement grant.","Ashley Ivanowicz appointed SVP, Human Resources; receives 100k stock option inducement grant.","Both options vest over 4 years with 12-month cliff; granted under Nasdaq inducement rule.","Company advancing AVTX-009 in Phase 2 LOTUS trial for hidradenitis suppurativa; data readout expected mid-2026.","Boyd previously led BD at Longboard, culminating in $2.6B acquisition by Lundbeck."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138081,"accession_number":"0001534120-25-000005","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-09-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Avalo Therapeutics appoints Kevin Lind to Board effective Oct 1; Dr. Almenoff resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kevin Lind appointed to Board effective Oct 1, 2025; will serve on Audit Committee and receive option for 40,200 shares vesting over 3 years.","Lind previously led Longboard Pharmaceuticals to $2.6B acquisition by Lundbeck in 2024; was EVP/CFO at Arena Pharmaceuticals.","June Almenoff resigns as director effective Oct 1; her equity awards modified to vest fully and options extended to Sept 30, 2026.","Company advancing Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138080,"accession_number":"0001628280-25-038570","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo Q2 2025 net loss $20.8M; cash $113.3M; Phase 2 LOTUS >75% enrolled, topline mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $20.8M in Q2 2025 ($1.92 per share) compared to net income of $98.5M ($4.21 basic EPS) in Q2 2024, driven by warrant-related items.","Cash and short-term investments $113.3M as of June 30, 2025; expected to fund operations into 2028.","Phase 2 LOTUS trial (AVTX-009 in hidradenitis suppurativa) enrollment >75% complete; topline data expected mid-2026.","R&D expenses increased to $14.1M from $4.6M, largely due to the Phase 2 LOTUS trial.","Rita Jain, M.D. appointed to Board of Directors; brings clinical development and regulatory experience."],"consensus_eps_estimate":-1.4331,"consensus_eps_actual":-3.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155492,"accession_number":"0001628280-25-032232","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo posts updated investor presentation highlighting IL-1β pipeline focus","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Presentation dated June 2025 reiterates mission to advance novel IL-1β therapies for unmet medical needs.","No new clinical data, financial results, or guidance included in the investor deck.","Company to use presentation in meetings with investors; no material change in strategy disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155491,"accession_number":"0001628280-25-032011","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics appoints former ChemoCentryx CMO Rita Jain to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Rita Jain appointed to Avalo's Board of Directors effective June 17, 2025.","She previously served as EVP and CMO at ChemoCentryx, advancing Tavneos for ANCA vasculitis.","Received initial non-qualified stock option for 40,200 shares, vesting over three years.","Board also adopted Amended Non-Employee Director Compensation Plan to attract qualified directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155490,"accession_number":"0001628280-25-031818","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Avalo stockholders elect eight directors, approve say-on-pay and auditor ratification at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; top vote-getter Michael Heffernan with 8,022,534 shares for.","Say-on-pay advisory resolution approved with 8,003,142 votes in favor (99.7% of votes cast).","Ratification of Ernst & Young as independent auditor for FY 2025 passed with 9,782,455 votes for.","Approximately 90% of outstanding shares (9.79M of 10.83M) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155489,"accession_number":"0001628280-25-029639","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Avalo Therapeutics enters $75M ATM equity offering with TD Cowen, terminates prior Oppenheimer facility","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with TD Cowen for at-the-market offering of up to $75M in common stock.","Commission to TD Cowen is up to 3% of gross proceeds from sales.","Terminated prior ATM agreement with Oppenheimer (originally $50M) effective June 4, 2025; no penalties.","Offering is made under existing effective S-3 registration statement (File No. 333-271225)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155488,"accession_number":"0001628280-25-029225","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics posts updated investor presentation; content not disclosed in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted updated investor presentation on its website on June 4, 2025.","No specific financial or operational updates from the presentation were included in the filing.","Investors are directed to the company's website for full content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155487,"accession_number":"0001628280-25-024435","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo Q1 net loss $13.1M; cash $125M; Phase 2 HS data expected 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.1M ($1.25/shr) vs $121.3M in Q1 2024; prior-year included warrant and acquisition charges.","Cash and equivalents $125M at March 31, 2025; runway into 2027, extendable to 2028 by delaying new indications.","Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa on track; topline data expected in 2026.","Mike Heffernan appointed Chairman of the Board.","R&D expenses $9.1M (+$7M YoY) driven by LOTUS trial; G&A $5.5M (+$2.4M YoY) on stock compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155486,"accession_number":"0001628280-25-023442","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo posts updated investor presentation; no material new facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted an updated investor presentation on its website on May 8, 2025.","Presentation is intended for use in investor meetings; no specific financial or pipeline updates provided in the filing.","No earnings, clinical data, or guidance changes included in the 8-K or exhibit excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173971,"accession_number":"0001628280-25-014833","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics appoints Michael Heffernan as Chairman, separating roles from CEO Garry Neil","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Heffernan appointed Chairman of the Board, effective March 25, 2025; succeeds Dr. Garry Neil who remains CEO and Board member.","Heffernan brings experience building biopharma companies and executing exits; will guide pipeline including AVTX-009 in Phase 2 LOTUS trial for HS.","Company states sufficient capital to achieve potentially transformative data readout from LOTUS trial next year.","Board also approved Amended and Restated Non-Employee Director Compensation Plan to attract and retain qualified directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173970,"accession_number":"0001628280-25-013984","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo reports 2024 net loss of $35.1M; cash of $134.5M funds into at least 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $134.5M at Dec 31, 2024 vs $7.4M in 2023; runway into at least 2027.","Net loss $35.1M in 2024 ($7.94 basic EPS) vs $31.5M loss in 2023; diluted EPS -$20.91.","R&D expense $24.4M, up $10.7M, driven by Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa.","Topline data from Phase 2 LOTUS trial expected in 2026; second indication for AVTX-009 planned.","Appointed Jennifer Riley as Chief Strategy Officer effective January 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173969,"accession_number":"0001628280-25-001228","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics posts updated investor presentation; no specific financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Avalo posted an updated corporate presentation on its website on Jan 13, 2025.","The filing does not disclose any specific financial, pipeline, or strategic updates from the presentation.","No new earnings, guidance, or material events were announced in connection with the posting.","The only document attached is the presentation cover slide; investors must access the full deck for details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173968,"accession_number":"0001628280-25-000005","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2025-01-02T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer; grants 150k stock option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jennifer Riley appointed Chief Strategy Officer effective Jan 1, 2025; oversees corporate strategy and pipeline planning.","Base salary $450,000; discretionary annual bonus target up to 40% of base salary.","Received inducement stock option to purchase 150,000 shares, vesting over 4 years with 12-month cliff.","Severance includes 9 months base salary (12 months if termination within 6 months after Change in Control) and full option vesting.","Company advancing AVTX-009 (anti-IL-1β mAb) in LOTUS Phase 2 trial for hidradenitis suppurativa."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190940,"accession_number":"0001628280-24-049979","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics posts updated investor presentation; no material new details available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Avalo Therapeutics posted an updated investor presentation on its website on December 5, 2024.","The presentation is intended for use in meetings with investors; no specific financial or operational updates disclosed in the filing.","No earnings, guidance, or material events were reported; the filing is a routine business update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190939,"accession_number":"0001628280-24-046852","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo receives $69.4M from full warrant exercise; cash runway into at least 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $69.4M from exercise of 11,967,526 warrants at $5.796933/share; total private placement proceeds now $185M.","Cash runway expected into at least 2027, funding Phase 2 LOTUS trial and expansion of AVTX-009 program.","As of Nov 8, 2024: 10,463,633 common shares outstanding; 24,895.92 Series C Preferred shares convertible into 24.9M common shares subject to ownership limits.","CEO states focus on hidradenitis suppurativa trial and identifying next inflammatory indication for AVTX-009."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190938,"accession_number":"0001628280-24-045964","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo Q3 net income $23M; first patient dosed in Phase 2 LOTUS trial for HS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $23.0M for Q3 2024 vs net loss of $5.2M in Q3 2023; diluted net loss per share $2.83.","Cash $81.9M at Sep 30, 2024; subsequent $58.1M warrant exercise proceeds extend runway into at least 2027.","First patient dosed in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa; topline data expected 2026.","R&D expenses $9.5M, up from $1.2M YoY due to AVTX-009 trial initiation and development costs.","Total revenues minimal at $249K; operating loss $12.9M for the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-22.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":249000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190937,"accession_number":"0001628280-24-042478","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-10-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo doses first patient in Phase 2 LOTUS trial of AVTX-009 for hidradenitis suppurativa","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 LOTUS trial enrolling ~180 adults with moderate to severe hidradenitis suppurativa.","Two dose regimens of AVTX-009 vs placebo in 1:1:1 randomization over 16-week treatment phase.","Primary endpoint: proportion achieving HiSCR75 at Week 16; topline data expected in 2026.","CEO Garry Neil cited high potency potential for best-in-class treatment option.","AVTX-009 is a humanized monoclonal antibody targeting IL-1β with high affinity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207429,"accession_number":"0001628280-24-039764","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo posts updated investor presentation; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed 8-K on Sept 9, 2024 to announce availability of an updated investor presentation.","Presentation posted on company website; no specific financial or operational updates provided in filing or exhibit.","Ticker AVTX; presentation dated September 2024 but content beyond title slide not included in filing text.","Investor presentation will be used in meetings with investors; no guidance or material events announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207428,"accession_number":"0001628280-24-039221","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Avalo Therapeutics regains Nasdaq compliance on market value standard; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received written confirmation from Nasdaq on Sept 3, 2024 that market value exceeded $35M for 10 consecutive trading days.","Regains compliance with Nasdaq Listing Rule 5550(b)(2) (Market Value of Listed Securities Standard).","Previously received notice on May 20, 2024 for non-compliance with Stockholders' Equity Requirement.","Compliance regained resolves the deficiency; no further Nasdaq action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207427,"accession_number":"0001628280-24-037174","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Avalo shareholders approve equity plan increase to 3.55M shares, ESPP, and elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Fourth Amended and Restated 2016 Equity Incentive Plan, increasing share reserve to 3,548,882 shares with automatic annual increases through 2034.","Stockholders also approved Amended and Restated Employee Stock Purchase Plan, reserving 234,878 shares with automatic annual increases through 2034.","All seven director nominees were elected: June Almenoff, Mitchell Chan, Jonathan Goldman, Aaron Kantoff, Gilla Kaplan, Garry Neil, Samantha Truex.","Stockholders ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2024.","Proposal to approve issuance of shares for Series C Preferred conversion, warrant exercise, and AlmataBio milestone obligations was approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207426,"accession_number":"0001628280-24-036589","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo Therapeutics reports net loss of $22.8M in H1 2024; cash $93.4M; AVTX-009 Phase 2 enrollment on track for H2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $93.4M as of June 30, 2024; expected cash runway into 2027.","Net loss for six months ended June 30, 2024 was $22.8M, compared to $18.1M in same period 2023.","AVTX-009 IND for hidradenitis suppurativa active; Phase 2 LOTUS Trial first patient enrollment expected H2 2024.","Appointed Dr. Mittie Doyle as CMO and Paul Varki as CLO; Q2 2024 net income of $98.5M from warrant liability fair value change."],"consensus_eps_estimate":null,"consensus_eps_actual":-30.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207425,"accession_number":"0001628280-24-033437","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nasdaq grants Avalo Therapeutics 180-day extension to regain equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reported stockholders' equity of negative $112.5M as of March 31, 2024, falling short of Nasdaq's $2.5M minimum.","Received Nasdaq Staff deficiency notice on May 20, 2024 for non-compliance with Listing Rule 5550(b)(1).","On July 29, 2024, Nasdaq granted a 180-day extension to November 18, 2024 to regain compliance.","Company submitted a compliance plan; no assurance it will regain compliance by the deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207424,"accession_number":"0001628280-24-031923","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics appoints Mittie Doyle, M.D., as CMO; grants 234,000-share option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Doyle, former CMO at Aro Biotherapeutics, brings over 20 years of pharma/biotech experience.","She will lead Phase 2 LOTUS Trial for AVTX-009 in hidradenitis suppurativa.","Base salary of $500,000, target bonus of 40%, and inducement stock option for 234,000 shares vesting over 4 years.","Severance includes nine months' salary (12 months post-change-in-control), full option vesting, and COBRA.","Appointment effective July 15, 2024; employment agreement filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207423,"accession_number":"0001628280-24-031426","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics IND for AVTX-009 active; Phase 2 LOTUS trial in hidradenitis suppurativa to commence","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for AVTX-009 (anti-IL-1β mAb) allowing Phase 2 LOTUS trial in moderate-to-severe HS.","LOTUS is a randomized, placebo-controlled trial of ~180 adults with two AVTX-009 dose regimens; primary endpoint HiSCR75 at Week 16.","First patient enrollment expected in 2024; AVTX-009 acquired in late March 2024 with IND filed ~3 months later.","Company believes AVTX-009 may be best-in-class due to target, half-life, and potency allowing convenient dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224848,"accession_number":"0001628280-24-029564","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer; Grants Inducement Stock Option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Varki appointed Chief Legal Officer effective June 24, 2024; 20+ years pharma/biotech legal experience.","Compensation includes $465K base salary, up to 40% target bonus, $50K sign-on cash award (12-month clawback).","Inducement option to purchase 150,000 shares vesting over 4 years (1-year cliff); exercise price set at June 24 close.","Varki previously US General Counsel at Idorsia, SVP/GC at Braeburn/Egalet, and 12 years at GSK.","Severance: 9 months salary (12 on change in control), pro-rated bonus, accelerated option vesting, 12 months COBRA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224847,"accession_number":"0001628280-24-029428","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Avalo Therapeutics posts updated investor presentation; no specifics available","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted an updated corporate presentation on its website dated June 2024.","Presentation content is largely forward-looking statements and standard disclaimers.","No new clinical data, financial guidance, or material business developments disclosed.","Ticker AVTX; presentation intended for investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224844,"accession_number":"0001628280-24-029561","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K/A","filed_at":"2024-06-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Avalo amends 8K to restate AlmataBio 2023 financials; net loss up $153K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Restated AlmataBio net loss for April 28–Dec 31, 2023 to $812K from $659K, a $153K increase.","R&D expense corrected upward by $135K to $663K; G&A expense up $18K to $149K.","Restatement had no cash flow impact; cash and equivalents remained $1.767M at Dec 31, 2023.","Previously issued financials for AlmataBio are superseded by this restated filing.","Acquisition of AlmataBio by Avalo closed on March 27, 2024; this is Amendment No. 2 to the original 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224843,"accession_number":"0001628280-24-026140","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K/A","filed_at":"2024-06-03T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Avalo Therapeutics completes acquisition of AlmataBio; discloses audited financials and pro forma info","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["AlmataBio net loss of $659k from inception (April 28, 2023) to Dec 31, 2023; cash $1.8M, total assets $1.8M.","Acquired anti-IL-1β asset (AVTX-009) from Leap Therapeutics for $500k cash plus potential milestones up to $70M development/regulatory and $720M sales-based.","Deal closed March 27, 2024, structured as stock-for-stock: AlmataBio equity exchanged for Avalo common and non-voting convertible preferred stock.","Unaudited pro forma combined statements for year ended Dec 31, 2023 and Q1 2024 filed as Exhibit 99.2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224846,"accession_number":"0001628280-24-024920","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Avalo Therapeutics receives Nasdaq delisting notice for negative stockholders' equity of $112.6M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reported stockholders' equity of negative $112.6M in Q1 2024 10-Q, below $2.5M minimum.","Has 45 days (until July 5, 2024) to submit a compliance plan to Nasdaq Staff.","If plan accepted, Staff may grant up to 180-day extension to regain compliance.","No immediate effect on listing; common stock continues trading on Nasdaq under AVTX.","Company evaluating options; no assurance of regaining compliance or avoiding delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224845,"accession_number":"0001628280-24-022762","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo Q1 net loss $121.3M driven by warrant fair value charge; cash $110M into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $110.2M at March 31, 2024; expects runway through AVTX-009 Phase 2 data readout and into 2027.","Net loss $121.3M includes $79.3M loss from excess of warrant fair value over private placement proceeds and $27.5M acquired IPR&D expense.","Closed private placement for up to $185M gross; initial $115.6M received; warrants classified as liability with $194.9M fair value.","Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026; trial to start this year.","Strategic review underway for quisovalimab (AVTX-002) and AVTX-008 programs; no revenue in Q1 2024 vs $475K a year ago."],"consensus_eps_estimate":null,"consensus_eps_actual":-141.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244115,"accession_number":"0001628280-24-013783","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-03-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Avalo acquires AVTX-009 anti-IL-1β mAb, closes $115.6M private placement; 2023 net loss $31.5M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired AVTX-009 (anti-IL-1β mAb) via acquisition of AlmataBio for $15M in stock plus $7.5M at close; milestones up to $20M.","Closed private placement for up to $185M, initial $115.6M upfront; cash runway into 2027.","2023 net loss $31.5M ($114 per share); cash $7.4M at Dec 31, 2023.","Plans Phase 2 trial in hidradenitis suppurativa; topline data expected in 2026.","Warrants issued at $5.80 per share; as-converted shares ~23.4M after transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244114,"accession_number":"0001628280-24-013435","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","5.03","2.01","3.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"Avalo acquires Phase 2-ready anti-IL-1β mAb via merger with AlmataBio, raises $115.6M PIPE","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired AlmataBio for ~$15M in stock (171,605 common shares + 2,412 Series C Preferred), plus up to $27.5M in milestones.","Concurrent PIPE of $115.6M upfront (up to $185M total) led by Commodore Capital and TCGX; net proceeds ~$105M.","Lead asset AVTX-009 (anti-IL-1β mAb, ex-Eli Lilly) is Phase 2-ready for hidradenitis suppurativa; topline data expected 2026.","Cash runway extended into 2027; board expanded to 9 with appointments of Jonathan Goldman, Aaron Kantoff, Samantha Truex."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244113,"accession_number":"0001628280-24-002715","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Avalo regains Nasdaq minimum bid compliance; subject to 1-year panel monitor","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter January 30, 2024 confirming compliance with $1.00 bid price rule.","Reverse stock split on December 28, 2023 brought stock above $1.00 since December 29, 2023.","Mandatory panel monitor for one year from January 30, 2024; no cure period if noncompliant again.","If noncompliant during monitor, Nasdaq will issue delist letter; company can request hearing.","Failure to satisfy panel could result in delisting from Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261531,"accession_number":"0001628280-23-042817","cik":1534120,"company_name":"Avalo Therapeutics, Inc.","ticker":"AVTX","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Avalo Therapeutics executes 1-for-240 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 5:00 PM ET Dec 28, 2023; shares trade split-adjusted Dec 29 under AVTX.","Shares outstanding reduced from ~192.4M to ~801,611; fractional shares rounded up to whole share.","Split raises per-share price to satisfy Nasdaq Capital Market minimum bid price rule.","No change to authorized shares or par value; options/warrants adjusted proportionally.","New CUSIP 05338F306; Equiniti Trust Company acting as exchange agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":832375811.6804941,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-12-28T23:59:59+00:00|261531"}